CHINESE JOURNAL OF DRUG EVALUATION >

2025 , Vol. 42 >Issue 6: 492 - 492-496

DOI: https://doi.org/magtech-2025-09-02-00001

Analysis of the Clinical Trial Research for Diabetes Drugs Based on the China Drug Trials Platform

Expand
  • Clinical Trial Institution Office， Wuxi Huishan District People′s Hospital， Jiangsu Wuxi 214187， China

Received date: 2025-09-02

  Revised date: 2025-10-01

  Accepted date: 2026-01-07

  Online published: 2026-01-07

Fold

Abstract

Objective： To understand the trends and characteristics of clinical trials on diabetes drugs and its complications in the past six years， and to provide a reference basis for the development and clinical research in China. Methods： From the perspectives of registration years， trial phases， indications of trial drugs， and sources and mechanisms of action of trial drugs， a comprehensive analysis was conducted on the current status of clinical trials for diabetes and its complication treatments in China. Results： A total of 1449 clinical trials were selected， showing an overall increasing trend year by year. More than half of these are bioequivalence trials， with the primary indication for drug development being type 2 diabetes. Additionally， the number of trial drugs derived from biological and chemical sources accounts for approximately 50% each. In phase Ⅰ to Ⅳ clinical trials of diabetes drugs， the top drugs were GLP-1 receptor agonists. Conclusion： The number of clinical trials of diabetes drugs in China has steadily increased， the research and development of generic drugs has been active， and the research and development of innovative drugs has focused on GLP-1 drugs. In the future， the clinical trial design of diabetes drugs should pay more attention to multi target and individualized strategies， in order to obtain the comprehensive metabolic benefits of diabetes patients.

Key words： ; font-size:medium; ">Drug clinical trials； Diabetes； Bioequivalent test； Phase Ⅰ-Ⅳ clinical trials

Cite this article

FENG Junyi, LI Ye, ZHANG Bingchang, SHI Hui, YANG Jue . Analysis of the Clinical Trial Research for Diabetes Drugs Based on the China Drug Trials Platform[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2025 , 42(6) : 492 -492-496 . DOI: magtech-2025-09-02-00001

References

 [1] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022： a pooled analysis of 1108 population-representative studies with 141 million participants [J]. Lancet， 2024， 404(10467)： 2077-2093.
     [2] 中华医学会糖尿病学分会. 中国糖尿病防治指南(2024版)[J]. 中华糖尿病杂志， 2025， 17(1)： 124.
     [3] Limin Wang， Wen Peng， Zhenping Zhao，et al. Prevalence and treatment of diabetes in China， 2013-2018 [J]. JAMA， 2021， 326(24)： 2498-2506.
     [4] Allie Seminer， Alfredi Mulihano， Clare O′Brien， et al. Cardioprotective glucose-lowering agents and dementia risk： a systematic review and Meta-analysis[J]. JAMA Neurol， 2025， 82(5)： 450-460.
     [5] Huilin Tang， William T Donahoo， Steven T DeKosky， et al. GLP-1RA and SGLT2i medications for type 2 diabetes and alzheimer disease and related dementias [J]. JAMA Neurol， 2025， 82(5)： 439-449.
     [6] Faith Aikaeli， Tsi Njim， Stefanie Gissing， et al.Prevalence of microvascular and macrovascular complications of diabetes in newly diagnosed type 2 diabetes in low-and-middle-income countries： a systematic review and meta-analysis[J]. PLOS Glob Public Health， 2022， 2(6)：e0000599.
     [7] Subrat Kumar Bhattamisra， Hui Min Koh， Shin Yean Lim， et al. Molecular and biochemical pathways of catalpol in alleviating diabetes mellitus and its complications[J]. Biomolecules， 2021， 11(2)： 323.
     [8] 吴光超， 宋健平， 杨涛， 等. 连梅颗粒对2型糖尿病GK大鼠的降糖作用[J]. 中成药， 2021， 1： 187-190.
     [9] Wei Xiang， Zhining Xia， Li Xu. UPLC-MS/MS Profiling， Antioxidant， α-glucosidase inhibitory， cholinesterase inhibitory， and cardiovascular protection potentials of jialing 20 (Morus multicaulis Perr.) mulberry branch extract[J]. Foods， 2021， 10(11)： 2659.
     [10] Xiuxin Zhong， Shaojing Lin， Mingxia， et al. The global status of bioequivalence trials： a comprehensive clinical trial landscape analysis based on the trialtrove database [J]. Deng Drug Discov Today， 2024， 29(12)： 104223.
     [11] 臧雪锋， 钱春艳， 潘玉芬， 等. 多学科协作在药物Ⅰ期/BE 临床试验中受试者风险管理的应用研究进展[J]. 医药前沿， 2023，13(11)： 44-49.
     [12] 中国研究型医院学会糖尿病学专业委员会.胰高糖素样肽-1受体激动剂联合胰岛素治疗2型糖尿病专家共识（2025版）[J]. 中华糖尿病杂志， 2025， 17(4)： 421-430.
     [13] Hideki Furukawa， Yasufumi Miyamoto， Yasuhiro Hirata， et al. Design and identification of a GPR40 full agonist (SCO-267) possessing a 2-carbamoylphenyl piperidine moiety[J]. J Med Chem， 2020， 63(18)： 10352-10379.
     [14] Linong Ji， Rikke M Agesen， Stephen C Bain，et al. Efficacy and safety of oral semaglutide vs sitagliptin in a predominantly Chinese population with type 2 diabetes uncontrolled with metformin： PIONEER 12， a double-blind， Phase Ⅲa， randomised trial[J]. Diabetologia， 2024， 67(9)： 1800-1816.
     [15] Sanjay Kalra， Awadhesh Kumar Singh， Sambit Das， et al. Sitagliptin as an add-on therapy to other glucose-lowering agents in patients with type 2 diabetes mellitus： a narrative review[J]. J Assoc Physicians India， 2025， 73(4)： e13-e18.
     [16] Mulualem Tesfaye Birhan， Teklie Mengie Ayele， Fikire Wondimu Abebe， et al. Effect of bromocriptine on glycemic control， risk of cardiovascular diseases and weight in patients with type 2 diabetes： a systematic review[J]. Diabetol Metab Syndr， 2023， 15(1)： 151.
     [17] Priyansh Patel， Amulya Adusumilli， Dharaneswari Hari Narayanan，et al. Evaluation of efficacy of bromocriptine as a therapeutic modality in the treatment of diabetes mellitus： a systematic review[J]. Cureus， 2023， 15(7)： e41931.
Options
Outlines

/

〈 〉

[an error occurred while processing this directive]